Product nameAnti-Wnt7a antibody
See all Wnt7a primary antibodies
DescriptionRabbit polyclonal to Wnt7a
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Chicken, Chimpanzee, Gorilla, Orangutan
Synthetic peptide corresponding to Human Wnt7a aa 250 to the C-terminus conjugated to keyhole limpet haemocyanin.
(Peptide available as
- Recombinant human Wnt7a protein (ab116171) can be used as positive control in WB. In Western Blot, ab100792 gave a positive signal in Human kidney tissue lysate. This antibody gave a positive result in ICC in HepG2 cells.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Note: Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab100792 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 41 kDa (predicted molecular weight: 39 kDa).
Abcam recommends using 5% BSA as the blocking agent.
|ICC/IF||Use a concentration of 5 µg/ml.|
FunctionLigand for members of the frizzled family of seven transmembrane receptors. Probable developmental protein. Signaling by Wnt-7a allows sexually dimorphic development of the mullerian ducts.
Tissue specificityExpression is restricted to placenta, kidney, testis, uterus, fetal lung, and fetal and adult brain.
Involvement in diseaseDefects in WNT7A are the cause of limb/pelvis-hypoplasia/aplasia syndrome (LPHAS) [MIM:276820]; also known as absence of ulna and fibula with severe limb deficiency. LPHAS is a limb-malformation disorder characterized by various degrees of limb aplasia/hypoplasia and joint dysplasia.
Defects in WNT7A are a cause of Fuhrmann syndrome (FUHRS) [MIM:228930]; also known as fibular aplasia or hypoplasia femoral bowing and poly- syn- and oligodactyly. Fuhrmann syndrome is a distinct limb-malformation disorder characterized also by various degrees of limb aplasia/hypoplasia and joint dysplasia.
Sequence similaritiesBelongs to the Wnt family.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
- Protein Wnt-7a antibody
- Protein Wnt-7a precursor antibody
- Proto oncogene Wnt7a protein antibody
Anti-Wnt7a antibody (ab100792) at 1 µg/ml + Human kidney tissue lysate - total protein (ab30203) at 10 µg
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 39 kDa
Observed band size: 41 kDa why is the actual band size different from the predicted?
Additional bands at: 15 kDa, 28 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 16 minutes
ICC/IF image of ab100792 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab100792, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899, DyLight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 4% PFA fixed (10 min) HeLa, Hek293 and MCF7 cells at 5µg/ml, and in 100% methanol fixed (5 min) HepG2 and MCF7 cells at 5µg/ml.
This product has been referenced in:
- Wang L et al. miR-127 suppresses gastric cancer cell migration and invasion via targeting Wnt7a. Oncol Lett 17:3219-3226 (2019). Read more (PubMed: 30867752) »
- Vallon M et al. A RECK-WNT7 Receptor-Ligand Interaction Enables Isoform-Specific Regulation of Wnt Bioavailability. Cell Rep 25:339-349.e9 (2018). Read more (PubMed: 30304675) »